Ruxolitinib Cream Could Become A Novel Treatment for Vitiligo
A pair of AAD VMX studies show long-term repigmentization is possible with the JAK inhibitor. An expert explains why the drug could make history.
New Data Highlights Etrasimod’s Potential for Atopic Dermatitis
The oral S1P receptor modulator has promise to break new ground for disease modification.
The Potential of Baricitinib for Alopecia Areata
Brett King, MD, PhD, discusses new ground that that oral JAK inhibitor breaks in the alopecia areata therapeutic field.
Ruxolitinib Cream Improves Patient-Reported Outcomes in Atopic Dermatitis
The investigative JAK inhibitor therapy provided significantly better skin clearance and resolved pain at 8 weeks with 2 different doses.
COVID-19 and Dermatologic Manifestations: What We Know So Far
Esther Freeman, MD, PhD, talks about the various levels of dermatologic severity associated with COVID-19.
Rebecca Kazin, MD: Cosmetic Dermatology Trends, Technologies, and Practices
Rebecca Kazin, MD, offers some insight into her cosmetic dermatology practices, including a new hair product that she developed.
Dupilumab Sustains Pediatric Atopic Dermatitis Improvement at 52 Weeks
Phase 3 open-label extension data suggest young patients may even improve skin clearance scores after a year on the biologic therapy.
Bimekizumab Betters Plaque Psoriasis Clearance Versus Secukinumab at 48 Weeks
A comparison of the IL-17 inhibitors suggest the more dynamic pathway-targeting biologic is more efficacious, but linked to more oral candidiasis.
Neal Walker, MD: Investigating a Topical Treatment for Warts
There are currently no FDA-approved prescription treatments for common warts, instead dermatologists must rely on painful alternatives like cutting, burning, and freezing.
Patrick Burnett, MD, PhD: Pipeline Progress of VP-102 for Molluscum Contagiosum
Following the completion of 2 pivotal trials, a new drug application for VP-102 will be submitted later this year.
Simon Murray, MD: Diagnosis and Treatment of Onychomycosis
Onychomycosis—fungal infection of the nail—is a common medical problem. Treatments are widely available, but relapse is common.
Larry Green, MD: Efficacy of Halobetasol & Tazarotene Lotion
In a post hoc analysis, Green and colleagues examined the effect of halobetasol and tazarotene lotion on plaque psoriasis in a Hispanic population.
Larry Green, MD: Halobetasol & Tazarotene Lotion in a Hispanic Population
Green introduces the combination lotion tested in this clinical trial of patients with moderate-to-sever plaque psoriasis.
Simon Murray, MD: AAD Recommendations for Acne Treatment
Recommendations for acne treatment drawn from AAD position paper and presentations.
Ken Gordon, MD: Role of Placebo in the UltIMMa Trials
Even in trials like UltIMMA that compare 2 drugs, a placebo control grounds the data, says Ken Gordon, MD.
James Q. Del Rosso, DO: Unlocking Isotretinoin's Benefits
The nodular acne therapy has been a staple treatment for 3 decades, yet new AAD data showed it could still be better utilized in patients.
John Durkin, MD: Confocal Microscopy and its Benefits
Confocal microscopy is an emerging technique that can offer a non-invasive alternative to biopsy.
Hyperhidrosis Associated with Higher Anxiety, Depression, ADD
The prevalence of anxiety, depression, and ADD was higher in patients with this excessive sweating disorder than the general population.
Lidose-Isotretinoin Sustains Long-Term Acne Benefit Without Food Intake
A new, long-term assessment of phase 4 data shows a twice-daily regimen of the common acne therapy can retain patient benefits weeks after treatment ends.
Ken Gordon, MD: Clinical Implications of the UltIMMa Trials of Risankizumab
Aside from the efficacy and safety of risankizumab, Gordon addresses the convenience, ease of use, and persistence of efficacy for patients with psoriasis.
Melinda Gooderham, MD: Clinical Implications of the reSURFACE 2 Trial
Gooderham addresses what the 3-year results of the reSURFACE 2 trial of tildrakizumab for plaque psoriasis mean for prescribers.
Ken Gordon, MD: Insights on Risankizumab for Plaque Psoriasis
The analysis of the UltIMMa 1 & 2 trials of risankizumab demonstrated efficacy and safety in the treatment of moderate-to-severe plaque psoriasis.
Dedee Murrell, MD: Results of the Believe-PV Pemphigus Vulgaris Trial
Investigational treatment PRN1008 demonstrated efficacy in this difficult-to-treat condition.
Melinda Gooderham, MD: 3-Year Results of the reSURFACE 2 Trial
This extension study investigated the long-term efficacy and safety of tildrakizumab for patients with plaque psoriasis.
Tildrakizumab Improves Psoriasis Patient Quality of Life
Results from the reSURFACE 1 phase 3 trial shows the biologic is beneficial to patient rates of anxiety, pain, and depression.
Patrick Burnett, MD, PhD: More Data from CAMP 1 & 2
Patrick Burnett shares about the secondary endpoints and safety data of the CAMP 1 & 2 clinical trials.
Dedee Murrell, MD: Safety of PRN1008 for Pemphigus Vulgaris
The phase 2 Believe-PV study observed few adverse events in patients with pemphigus vulgaris.
Patrick Burnett, MD, PhD: Results of CAMP 1 & 2 in Molluscum Contagiosum
Patrick Burnett reports impressive topline results from the CAMP 1 & 2 studies of investigational treatment VP-102.
Dedee Murrell, MD: Significance of the Believe-PV Trial in Pemphigus Vulgaris
Though there are few treatments for pemphigus vulgaris, a rare disease, the Believe-PV trial of PRN1008 raises the possibility of a new, better option.
Ixekizumab Sustains Plaque Psoriasis Severity Improvement Over 1 Year
Investigators assessed patients’ scores for body surface area, static Physician Global Assessments, and Dermatology QoL Index at 1 month post-index, and at three-month intervals both pre- and post-index.
